These treatments prevented the decrease of phospho-Akt and phospho-GSK-3β levels induced by ischemia, reducing the ischemia-induced increase of phospho-DRP2 by “active” dephospho-GSK-3β, and improving the integrity and protection of axons/dendrites against ischemic injury. The gene discussed is DRP2; the disease is ischemia.